All In Biotech

NDA 016750 · Amphastar Pharms INC

Cortrosyn

Cosyntropin · Injection · Adrenocorticotropic Hormone

Novel

Last checked: Nov 20, 2026Latest source record: Dec 22, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1970

Apr 22, 1970

Approved uses

1

Original approval plus efficacy supplements

Registered trials

30

3 Phase 3, 2 recruiting

FAERS reports

220

188 serious, 27 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 27, 2026.

CORTROSYN is indicated, in combination with other diagnostic tests, for use as a diagnostic agent in the screening of adrenocortical insufficiency in adults and pediatric patients. CORTROSYN is an adrenocorticotropin hormone indicated, in combination with other diagnostic tests, for use as a diagnostic agent in the screening of adrenocortical insufficiency in adults and pediatric patients. (1)

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 22, 1970 Original approval · Type 1 - New Molecular Entity
1 products under this application
  • CORTROSYN · COSYNTROPIN 0.25MG/VIAL · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Cosyntropin" as an intervention, any sponsor and status, largest first.

All 30 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • foetal growth restriction24
  • foetal exposure during pregnancy23
  • hypoglycaemia20
  • hypotension18
  • dyspnoea13
  • pneumonia13
  • nausea12
  • hyperkalaemia11
  • sepsis11
  • adrenal insufficiency10
  • rash10
  • dizziness8

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20046
20052
20063
20077
20085
20094
20105
20119
201212
20136
20149
20155
201613
20171
201810
201919
202014
202123
202215
202314
202410
202515
202613

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Cortrosyn* (Cosyntropin*) · HCPCS J0834

2024 spending

$76K

Beneficiaries

2,826

3,012 claims

Per beneficiary

$27

2024 ASP limit $25.63 per unit

View as table
YearSpending
2020$127,878
2021$105,648
2022$93,733
2023$83,873
2024$75,645

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 121 on PubMed

Sponsor: Amphastar Pharms INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.